Optometry & Ophthamology
Occuity is designing and developing a range of handheld optical non-contact devices for pachymetery, axial length, pupillometry and Keratometry in both human and veterinary optometry.
Following years of research and based on our patented technology (nine granted patents, five pending and one further in draft), we're bringing to market affordable, handheld devices with the measuring and non-contacting capabilities found in existing optical desktop devices at a price point more akin to the handheld contacting ultrasound devices.
We believe the nature and pricing of our devices will prove disruptive to the current optometry market.
The first of Occuity's revolutionary optical handheld devices, the PM1 Pachymeter offers many advantages over existing ultrasound technology and allows for a non-clinical operator to take a corneal centre thickness measurement quickly and easily.
Our Ophthalmic Product Series
The AX1 will build upon the novel optical technology utilised within the PM1 to enable direct axial length measurement - all within a compact handheld device. Utilising a similar form factor to the PM1 will help Occuity accelerate the development of the AX1.
Following on from the PM1 and AX1, Occuity will look to add additional functionality to our technology platform. The PM2 will provide pachymetry alongside additional measurement sets which is likely to include pupillometry and keratometry.
The handheld, non-contact capabilities of our products makes them ideal for use in the veterinary sector.
Occuity is looking for partners in veterinary/veterinary ophthalmology to explore the use of our technology and products. Please contact us for more information.
The Pachymeter Development
The Pachymeter has come a long way since our first prototype device.
The first pachymeter prototype is tested the scanning optics and data collection but linked to a separate PC to process the data and supply power.
The next prototype miniaturized the technology from the first device, added in a camera and rear screen and moved to a self-contained, battery-powered version complete with its own processing power.
The production prototype is close to the final device and contains enhancements to the second device with a better camera, screen, processing, and connectivity options.
This device is planned to undergo CE and FDA approval and will be used in the clinical trials in 2022.